Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2016-11-17 Report Publication Anno…
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Notice of Interim Results
Report Publication Announcement Classification · 1% confidence The document is very short (2452 characters) and its primary purpose is to announce *when* the company will release its interim results (for the half year ended 30 September 2016) on a future date (Monday 5 December 2016). It explicitly states, 'Notice of Interim Results'. According to Rule 2 (The 'MENU VS MEAL' RULE), a short document announcing the publication of a report falls under Report Publication Announcement (RPA). It is not the Interim Report (IR) itself, nor is it a general regulatory filing (RNS), as it fits the specific RPA definition better.
2016-11-17 English
Grant of Options
Remuneration Information Classification · 1% confidence The document is identified by the 'RNS Number' header and the closing statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details the 'Grant of Options' to Persons Discharging Managerial Responsibility (PDMRs) under the Long Term Incentive Plan (LTIP). This type of announcement, concerning insider transactions or executive compensation/incentives, is often classified under Director's Dealing (DIRS) or sometimes as a general Regulatory Filing (RNS). Since the document explicitly details share transactions/grants involving management (PDMRs), it strongly aligns with the definition of Director's Dealing (DIRS). However, given the structure as a formal RNS announcement detailing option grants to management, and the presence of the RNS identifier, it fits the general regulatory announcement category. Since DIRS specifically covers 'Report of personal share transactions by company directors and executives (insider trades)', and option grants fall under this umbrella, DIRS is the most specific fit. If DIRS were not available, RNS would be the fallback. Given the options, DIRS is the most precise classification for executive option grants.
2016-11-01 English
Exercise of options
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details the issuance of new ordinary shares following an employee's exercise of share options and the subsequent application for admission to trading. This is a specific corporate action announcement related to capital structure changes (share issuance) but is distributed via the Regulatory News Service (RNS). While 'SHA' (Share Issue/Capital Change) is relevant to the content, the primary nature of the document, as indicated by the source identifier (RNS Number) and the distribution method, points towards a general regulatory announcement. Given the options, 'RNS' is the most accurate classification for a document explicitly labeled as an RNS release, especially when the content is a specific, non-standard filing type. However, since the core event is a share issue, 'SHA' is also a strong candidate. Comparing SHA (Share Issue/Capital Change) and RNS (General regulatory announcements/fallback): Since the document explicitly details the issuance of shares and the resulting total share count, it fits the definition of 'SHA'. RNS is the distribution channel, but SHA describes the substance. Given the specific nature of the event (issuance of shares following option exercise), SHA is more precise than the general RNS fallback.
2016-10-28 English
VERONA PHARMA PLC - Second Venture and Innovation Award from the CF Trust
Environmental & Social Information Classification · 1% confidence The document is a press release announcing that Verona Pharma plc has received a 'second Venture and Innovation Award from the Cystic Fibrosis Trust' to fund a clinical study for their drug candidate RPL554. It details the purpose of the funding, mentions upcoming pre-clinical data presentations at a conference, and includes quotes from management. This type of announcement, focusing on a specific corporate development (grant/award) that is not a mandatory periodic financial filing (like 10-K or IR) or a standard earnings release, fits best under the general 'Regulatory Filings' (RNS) category as a significant corporate news item, or potentially 'Capital/Financing Update' (CAP) due to the funding aspect, but RNS is broader for general news releases. Given the context of a PR Newswire release detailing a specific, non-financial operational/research milestone, RNS is the most appropriate general classification for non-standard announcements.
2016-10-26 English
VERONA PHARMA PLC - Notice of Cancellation of Trading on Xetra
Delisting Announcement Classification · 1% confidence The document is a short press release from Verona Pharma plc announcing an application to cancel its secondary trading listing on the Xetra platform of the Frankfurt Stock Exchange. It specifies the last day of trading (November 24, 2016). This action—the removal of a stock listing—is a significant corporate event related to market presence and capital structure, but it does not fit neatly into standard financial reporting categories like 10-K, ER, or IR. It is a specific regulatory/market announcement. Since it is not a dividend notice (DIV), director dealing (DIRS), capital change (CAP/SHA), or a general regulatory filing fallback (RNS), the most appropriate category for a specific, non-standard corporate action announcement that affects market access is 'Delisting Announcement' (DLST). The document length is short, but the content is the announcement itself, not a notice about an attached report.
2016-10-19 English
Exercise of options
Share Issue/Capital Change Classification · 1% confidence The document is identified by the 'RNS Number' header and the closing statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content explicitly announces the 'Exercise of Options' leading to the issuance of new ordinary shares and the subsequent change in the total number of shares in issue. This directly relates to a change in the company's capital structure via share issuance, which aligns with the definition for 'Share Issue/Capital Change' (SHA). Although it is an RNS announcement, the specific nature of the announcement (share issuance/capital change) makes SHA a more precise classification than the general fallback RNS.
2016-09-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.